TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the successful closing of its oversubscribed $120 million Series B financing round.
TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
TRIANA Biomedicines, Inc. (Triana) today announced their launch with $110 million in total funding to establish a best-in-class, scalable platform to discover and develop “molecular glues”. Triana’s platform aims to generate products that stabilize pre-existing or create de novo interactions between two proteins and alter the fate or functionality of the disease target. Molecular glues may allow for the pursuit of highly disease-relevant targets long considered undruggable or inadequately addressed by traditional drug discovery approaches.
